Modeling and Simulation of Development of Anti-drug Antibodies

CBER - Office of Biostatistics and Epidemiology
United States MD Silver Spring


An ORISE research fellowship is available immediately at the Food and Drug Administration (FDA) in Silver Spring, Maryland. The successful candidate will participate in the development of an immune response model to predict immunogenicity and simulate anti-drug antibody development among hemophilia patients treated with recombinant factor products. The goal of this project is the development of a computational tool to enhance efficacy and safety evaluation of current and next-generation engineered therapeutic products, leading to personalized, optimal treatment regimens for hemophilia patients. Under the guidance of a mentor, the participant will help to develop and apply novel techniques to model and simulate interactive components of the human immune system, as well as perform literature reviews, data collection, model development, presentation of research results, and preparation of scientific manuscripts.

This position is a post-doctoral fellowship through the Oak Ridge Institute for Science and Education (ORISE). Candidates will be offered competitive salary and health benefits.


The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by June 1, 2019. Degree must have been received within five years of the appointment start date. This position is only open for US citizens, permanent residents (Green Card holders) or individuals residing in US for 3 years during the last 5 years on a valid US visa. Preferred skills/experience are
• knowledge of immunology, modeling and programming skills,
• experience with differential equations,
• excellent written and oral communication skills,
• solid background and skills in both biology and computing science

Start date

As soon as possible

Start date

To be determined

How to Apply

Highly motivated candidates should apply through (Reference Code: FDA-CBER-2019-0023)